martes, 1 de abril de 2014

National Guideline Clearinghouse | (1) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. (2) Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. 2010 addendum. (3) Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. 2013 addendum.

full-text ►

National Guideline Clearinghouse | (1) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. (2) Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. 2010 addendum. (3) Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. 2013 addendum.








    National Institute for Health and Care Excellence (NICE)
    National Guideline Clearinghouse (NGC)

    March 31, 2014

    Guideline Title
    (1) Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. (2) Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. 2010 addendum. (3) Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. 2013 addendum.
    Bibliographic Source(s)
    National Institute for Health and Care Excellence (NICE). Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people. London (UK): National Institute for Health and Care Excellence (NICE); 2013 Nov. 52 p. (Technology appraisal guidance; no. 300). 
    National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. 2010 addendum. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Sep. 46 p. (Technology appraisal guidance; no. 200). 
    National Institute for Health and Clinical Excellence (NICE). Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. London (UK): National Institute for Health and Clinical Excellence (NICE); 2006 Aug. 31 p. (Technology appraisal guidance; no. 106). 
    Guideline Status
    This is the current release of the guideline.

    No hay comentarios:

    Publicar un comentario